Chronic inducible urticaria

Summary

Chronic inducible urticaria (MONDO:0956969) is a disease and 11 clinical trials. Top therapeutic interventions include omalizumab, barzolvolimab, and ligelizumab. A subtype of chronic urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic inducible urticaria
Mondo ID	MONDO:0956969
DOID	DOID:0080748
UMLS	C5197720
MedGen	1678519
Is cancer (heuristic)	no

Disease family

This is a subtype of chronic urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › chronic urticaria › chronic inducible urticaria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE3	3
PHASE2	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05976243	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT07266402	PHASE3	RECRUITING	A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT05024058	PHASE3	TERMINATED	Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
NCT06931405	PHASE2	RECRUITING	Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT05405660	PHASE2	COMPLETED	A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT06353971	PHASE1/PHASE2	TERMINATED	A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
NCT06603220	PHASE2	COMPLETED	A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
NCT07181369	PHASE1	RECRUITING	A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
NCT07540910	PHASE1	RECRUITING	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT05960708	PHASE1	COMPLETED	A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
NCT06050928	PHASE1	COMPLETED	Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OMALIZUMAB	4	1
BARZOLVOLIMAB	3	2
LIGELIZUMAB	3	1
REMIBRUTINIB	3	1
BRIQUILIMAB	2	1